How Diabetes and Other Comorbidities of Elderly Patients and Their Treatment Influence Levels of Glycation Products

Aleksandra Kuzan, Emilia Królewicz, Irena Kustrzeba-Wójcicka, Karolina Lindner-Pawłowicz and Małgorzata Sobieszczańska
Additional contact information
Aleksandra Kuzan: Department of Medical Biochemistry, Wroclaw Medical University, 50-368 Wroclaw, Poland
Emilia Królewicz: Department of Medical Biochemistry, Wroclaw Medical University, 50-368 Wroclaw, Poland
Irena Kustrzeba-Wójcicka: Department of Medical Biochemistry, Wroclaw Medical University, 50-368 Wroclaw, Poland
Karolina Lindner-Pawłowicz: Clinical Department of Geriatrics, Wroclaw Medical University, 50-369 Wroclaw, Poland
Małgorzata Sobieszczańska: Clinical Department of Geriatrics, Wroclaw Medical University, 50-369 Wroclaw, Poland

IJERPH, 2022, vol. 19, issue 12, 1-16

Abstract: Medical care for geriatric patients is a great challenge, mainly due to various overlapping deficits relevant to numerous coexisting diseases, of which the most common are diabetes mellitus and atherosclerosis. In the case of diabetes, the glycation process is intensified, which accelerates atherosclerosis development and diabetic complications. Our goal was to investigate the relationship between the classical biochemical parameters of diabetes and atherosclerosis, as well as parameters which may indicate a nephropathy, and the parameters strictly related to glycation, taking into account the pharmacological treatment of patients. Methods: We analyzed the patients’ serum concentrations of fluorescent glycation product—pentosidine, concentrations of soluble receptors for advanced glycation products (sRAGE), lipoprotein receptor-1 (LOX-1), galectin 3 (GAL3), scavenger receptor class A (SR-A), and scavenger receptor class B (SR-BI), as well as the level of lipid peroxidation and free amine content. Among the identified correlations, the most interesting are the following: sRAGE with triglycerides (r = 0.47, p = 0.009), sRAGE with SR-BI (r = 0.47, p = 0.013), SR-BI with LOX-1 (r = 0.31, p = 0.013), and SR-BI with HDL (r = −0.30, p = 0.02). It has been shown that pentosidine and reactive free amine contents are significantly higher in elderly patients with ischemic heart disease. Pentosidine is also significantly higher in patients with arterial hypertension. Malondialdehyde turned out to be higher in patients with diabetes mellitus type 2 that was not treated with insulin or metformin than in those treated with both medications ( p = 0.052). GAL3 was found to be lower both in persons without diabetes and in diabetics treated with metformin ( p = 0.005). LOX-1 was higher in diabetic patients not treated with metformin or insulin, and lowest in diabetics treated with both insulin and metformin, with the effect of metformin reducing LOX-1 levels ( p = 0.039). Our results were the basis for a discussion about the diagnostic value in the clinical practice of LOX-1 and GAL3 in geriatric patients with diabetes and also provide grounds for inferring the therapeutic benefits of insulin and metformin treatment.

Keywords: aging; geriatric care; elderly diseases; diabetes mellitus type 2; glycation markers (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/12/7524/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/12/7524/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:12:p:7524-:d:842982

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().